CN107823625A - 一种治疗冠心病心肌梗死心绞痛心律失常心衰的中药散剂 - Google Patents
一种治疗冠心病心肌梗死心绞痛心律失常心衰的中药散剂 Download PDFInfo
- Publication number
- CN107823625A CN107823625A CN201711371634.8A CN201711371634A CN107823625A CN 107823625 A CN107823625 A CN 107823625A CN 201711371634 A CN201711371634 A CN 201711371634A CN 107823625 A CN107823625 A CN 107823625A
- Authority
- CN
- China
- Prior art keywords
- parts
- angina pectoris
- arrhythmia cordis
- heart failure
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 26
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 19
- 239000000843 powder Substances 0.000 title claims abstract description 17
- 206010003119 arrhythmia Diseases 0.000 title claims abstract description 9
- 230000006793 arrhythmia Effects 0.000 title claims abstract description 9
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 8
- 208000010125 myocardial infarction Diseases 0.000 title claims abstract description 6
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 10
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 10
- 241000545744 Hirudinea Species 0.000 claims abstract description 9
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 9
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 9
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 9
- 210000003056 antler Anatomy 0.000 claims abstract description 9
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims abstract description 9
- 241000208966 Polygala Species 0.000 claims abstract description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 6
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 6
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 6
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 6
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract 3
- 239000000463 material Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 13
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 210000005036 nerve Anatomy 0.000 abstract description 4
- 230000004217 heart function Effects 0.000 abstract description 3
- 230000020245 homoiothermy Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 210000004204 blood vessel Anatomy 0.000 abstract description 2
- 229940126678 chinese medicines Drugs 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 10
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 241001247821 Ziziphus Species 0.000 description 6
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 3
- 206010008469 Chest discomfort Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001544 dysphoric effect Effects 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010051093 Cardiopulmonary failure Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241001601725 Sthenias Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000303379 Styrax officinalis Species 0.000 description 1
- 235000001361 Styrax officinalis Nutrition 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000020509 sex determination Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000009396 suanzaoren Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000009561 tongxinluo Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000008945 zhigancao decoction Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/10—Peat; Amber; Turf; Humus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗冠心病心肌梗死心绞痛心律失常心衰的中药散剂,属于中药领域。桂枝2.5~3.5份,当归1.8~2.2份,红参1.8~2.2份,枣仁1.8~2.2份,远志1.8~2.2份,琥珀1.8~2.2份,三七1.8~2.2份,水蛭0.9~1.1份,炙甘草1.8~2.2份,干姜1.8~2.2份,菟丝子2.5~3.5份,鹿茸片1.8~2.2份,旋复花1.8~2.2份,代赭石1.8~2.2份。本发明温血益气,安神开窍,化瘀降浊,散寒填精,用于血脉不通,心痛胸闷,心律失常,心衰等心脏功能减弱者;疗效显著、安全可靠、无毒副作用,在改善患者心肌缺血的同时,做到诊断准确,无需辨证,即可用药,具有标本兼治的临床效果。
Description
技术领域
本发明属于中药领域,具体说是一种治疗冠心病的的中药组合物。
背景技术
冠状动脉粥样硬化性心脏病是指冠状动脉粥样硬化使血管狭窄或阻塞,和(或)因冠状动脉功能性改变(痉挛)导致心肌缺血缺氧或坏死而引起的心脏病,简称冠心病。心肌缺血是指心脏的血液灌注减少,导致心脏的供氧减少,心肌能量代谢不正常,不能支持心脏正常工作的一种病理状态。当某种原因导致心肌血液供血失衡,就构成了真正意义上的心肌缺血。而冠心病是引起心肌缺血最主要、最常见的病因。据《中国心血管病报告2015》报告,我国冠心病死亡率由2002年农村27.57/10万、城市39.66/10万,上升至2014年农村105.37/10万,城市107.5/10万,呈上升态势。2014年中国医院以缺血性心脏病出院人次占43.45万人次。因此改善心肌缺血治疗,刻不容缓。
冠心病,根据其主要临床症状,可归属于中医学“胸痹”、“心痛”的范畴。祖国医学中的胸痹,是指以胸部闷痛,甚则胸痛彻背,喘息不得卧为主症的一种疾病,轻者仅感胸闷如窒,呼吸欠畅,重者胸痛,甚则心痛彻背,背痛彻心。《素问·脏气法时论》中记载,“心病者,日中慧,夜半甚,平旦静”;“心病者,胸中痛,胁支满,胁下痛,膺背肩胛间痛,两臂内痛”。其症状描述非常类似于现代医学心肌缺血引起的心绞痛。
胸痹、心痛,其病位在心,涉及肝、脾、肾三脏。以素体阳虚,胸阳不振为病理基础;病理因素为阴寒,痰浊,瘀血相互为患。病理性质总属本虚标实。病理转化可以因实致虚,亦可以因虚致实,临床病因以太阳寒水逆袭太阳少阴以水克火最为常见,另三阴寒湿瘀血上逆,也不少见。心阴不足虚烦不得眠发展成心动悸脉结代为另一种常见病因。综上,胸痹心痛,从阴阳可以分为两种,一种是从桂枝甘草汤的心悸喜按的心阳不足发展成水饮凌心的桂枝真武理中汤证。另一种是从虚烦不得眠的酸枣仁汤证发展成心动悸脉结代的炙甘草汤证,黄连阿胶汤证。
目前应用于冠心病治疗的中药制剂种类很多,如通心络胶囊、冠心苏合丸,香港益安宁等,大多数药物其组方多采用芳香温通类、虫类药物为主,其效果多以治痰、瘀等标之所在,未能达到治本之效,同时上述药物未从中医整体论治的角度治疗心脏而以心治心,未能五脏用药。临床使用中需掌握中医辨证分型,辨证错误,用药即错。因此,对于非中医医师难以做到辨证正确,用药合理。
发明内容
本发明提供一种治疗冠心病心肌梗死心绞痛心律失常心衰的中药散剂,以解决以上现有技术的不足。
本发明以桂枝,当归温血行血为君,以枣仁,远志,琥珀安神通窍为臣,以红参,炙甘草,干姜,鹿茸,菟丝子益气填精为佐,以三七,水蛭,旋复花,代赭石通滞降浊为使,通过交通手足少阴随精神往来,另水火既济,使君,相二火枢机正常运转。并在阳明厥阴合机土—金、木—火升清降浊的推动力下起到破瘀通滞推陈致新的作用。同时促进心血正常运转。
本发明采取的技术方案是:由以下重量份的中药原料配制而成:
桂枝2.5~3.5份,当归1.8~2.2份,红参1.8~2.2份,枣仁1.8~2.2份,远志1.8~2.2份,琥珀1.8~2.2份,三七1.8~2.2份,水蛭0.9~1.1份,炙甘草1.8~2.2份,干姜1.8~2.2份,菟丝子2.5~3.5份,鹿茸片1.8~2.2份,旋复花1.8~2.2份,代赭石1.8~2.2份。
优选的:
桂枝3份,当归2份,红参2份,枣仁2份,远志2份,琥珀2份,三七2份,水蛭1份,炙甘草2份,干姜2份,菟丝子3份,鹿茸片2份,旋复花2份,代赭石2份。
本发明按中药制备散剂的方法,制备散剂。
本发明温血益气,安神开窍,化瘀降浊,散寒填精,用于血脉不通,心痛胸闷,心律失常,心衰等心脏功能减弱者;疗效显著、安全可靠、无毒副作用,在改善患者心肌缺血的同时,做到诊断准确,无需辨证,即可用药,具有标本兼治的临床效果。服用本发明的中药散剂,每日两次,每次1g,早10点、晚8点两次服用。
具体实施方式
实施例1
由以下重量份的中药原料配制而成:
桂枝2.5份,当归1.8份,红参1.8份,枣仁1.8份,远志1.8份,琥珀1.8份,三七1.8份,水蛭0.9份,炙甘草1.8份,干姜1.8份,菟丝子2.5份,鹿茸片1.8份,旋复花1.8份,代赭石1.8份;
按中药制备散剂的方法,制备散剂。
实施例2
由以下重量份的中药原料配制而成:
桂枝3份,当归2份,红参2份,枣仁2份,远志2份,琥珀2份,三七2份,水蛭1份,炙甘草2份,干姜2份,菟丝子3份,鹿茸片2份,旋复花2份,代赭石2份;
按中药制备散剂的方法,制备散剂。
实施例3
由以下重量份的中药原料配制而成:
桂枝3.5份,当归2.2份,红参2.2份,枣仁2.2份,远志2.2份,琥珀2.2份,三七2.2份,水蛭1.1份,炙甘草2.2份,干姜2.2份,菟丝子3.5份,鹿茸片2.2份,旋复花2.2份,代赭石2.2份;
按中药制备散剂的方法,制备散剂。
下边通过临床试验来进一步说明本发明的效果。
1.1、一般资料
60例临床研究病例选取于2013年3月至2014年6月在我院心内科住院的缺血性心脏病的患者。
1.2、诊断标准
诊断标准参照国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组报告《缺血性心脏病的命名级诊断标准》;加拿大心血管学会(CCS)心绞痛严重度分级;心绞痛症状评分及分级标准参照《中药新药临床研究指导原则(2002年)》进行诊断。
1.3、纳入标准
符合西医冠心病心绞痛、心绞痛分级Ⅱ、Ⅲ级,分度为轻度、中度诊断标准者;符合中医胸痹诊断标准者;患者年龄在40-70岁之间;心电图有缺血性改变者;自愿参加试验并签署知情同意书者。
1.4、排除标准
患者所患胸痛经检查证实为冠心病急性心肌梗死以及其他心脏疾病、甲亢、神经官能症、颈椎病、更年期症候群、胃及食管反流、胆心病等所致者;合并中重度高血压、重度心肺功能不全、重度心律失常、以及合并重度肝、肾、内分泌、造血系统等原发性疾病者;妊娠或准备妊娠或哺乳期妇女、精神病患者;过敏体质及对本试验中所用药物过敏者;半年内曾患急性心肌梗塞、脑血管意外或有严重创伤或手术史者;不符合纳入标准,不按规定用药,无法判断疗效或资料不全等影响疗效或安全性评定者。
1.5、剔除标准
不符合纳入标准而被误纳入者;受试者整个研究中未使用药物;受试者不按方案要求使用药物或使用了方案规定不允许使用的药物而影响疗效或安全性判定者。
1.6、脱落标准
出现严重不良事件、并发症和特殊生理变化,不宜继续接受试验者;试验过程中自行退出者;因其他各种原因疗程未结束退出试验、加重或死亡的病例。
1.7、治疗方法
将符合纳入标准的60例患者给予发明中药,每日1剂,分2次服用,疗程为2个月,电话随访观察疗效。
1.8、观察指标及疗效标准
观察治疗前、疗后心绞痛疗效、心电图改变、硝酸甘油停减率、西雅图心绞痛调查量表(SAQ)积分。同时治疗前后检测血、尿、便常规、肝功能、肾功能等安全性指标。出现不良反应随时记录。
参照《中药新药临床研究指导原则(2002年)》及中西医结合治疗冠心病心绞痛及心律失常座谈会《冠心病心绞痛及心电图疗效评定标准》。
2结果
2.1两组心绞痛疗效比较
治疗后,心绞痛疗效总有效率为76.67%。详见表1:
表1两组心绞痛疗效比较[例(%)]
2.2心电图疗效
经治疗后,心电图疗效总有效率为66.67%。详见表2:
表2两组治疗前后心电图疗效对比[例(%)]
2.3硝酸甘油停减率
治疗后,硝酸甘油停减率为78.33%。详见表3。
表3两组硝酸甘油停减率对比[例(%)]
2.4西雅图心绞痛调查量表(SAQ)积分比较
经治疗后,较治疗前能显著改善心绞痛积分,具有统计学意义(P<0.05)。详见表4。
表4两组西雅图心绞痛调查量表(SAQ)积分比较
注:*P<0.05;
2.5安全性检测
本研究共纳入60例患者,整个研究过程中无剔除、脱落病例。患者的血常规、尿常规、便常规、肝功能在治疗前后均无明显异常变化。整个研究过程中未出现严重不良反应及过敏反应。说明本发明药物,治疗心肌缺血在治疗剂量下安全且无毒副作用。
典型病例:
病例1:张某,男,65岁。患者10多年前因胸闷、气促、汗出不适在医院检查后确诊为冠心病(未行冠脉支架植入术)。此后口服药物治疗,病情仍反复发作并呈逐年加重趋势。2014年6月患者再次感胸闷不适,当地复查心脏彩超发现全心扩大,左心房50mm,左心室89mm,节段性室壁运动异常,轻度肺动脉高压,左心功能减低;心电图:心肌缺血,左室高电压。患者开始服用本发明散剂,半年后随访已见初效,胸闷发作减少,气促改善。复查心脏彩超左房44mm,左室79mm,EF39%。续用药3个月病情一直稳定,未再复查心脏彩超。
病例2:吴某,女性,54岁。该患者在2010年5月,突发胸部不适,头出汗到医院就诊,急查冠脉造影未见狭窄,心电图心肌缺血,当地确诊为冠心病(变异性心绞痛)。在服用西药7个月心绞痛发作无法控制,每天有2-4次心绞痛发作,每次约30秒至1分钟。入院查体:体温36.5℃,脉搏88次/分,呼吸16次/分,血压110/80mmHg。双肺呼吸音清,未闻及干湿性啰音。心尖搏动位于左侧第五肋间锁骨中线内0.5cm,心率88次/分,律齐,心前区无明显杂音。由于治疗效果欠佳,故患者于2011年6月开始服用本发明散剂,疗效显著,服药4个月心绞痛已消失。2011年11月随访经医院检查,血脂、血压、血粘度等各项指标均正常。患者服药9个月后于2012年4月底停药至今,没有发生一次心绞痛现象。
Claims (2)
1.一种治疗冠心病心肌梗死心绞痛心律失常心衰的中药散剂,其特征在于:由以下重量份的中药原料配制而成:
桂枝2.5~3.5份,当归1.8~2.2份,红参1.8~2.2份,枣仁1.8~2.2份,远志1.8~2.2份,琥珀1.8~2.2份,三七1.8~2.2份,水蛭0.9~1.1份,炙甘草1.8~2.2份,干姜1.8~2.2份,菟丝子2.5~3.5份,鹿茸片1.8~2.2份,旋复花1.8~2.2份,代赭石1.8~2.2份。
2.根据权利要求1所述的一种治疗冠心病心肌梗死心绞痛心律失常心衰的中药散剂,其特征在于:由以下重量份的中药原料配制而成:桂枝3份,当归2份,红参2份,枣仁2份,远志2份,琥珀2份,三七2份,水蛭1份,炙甘草2份,干姜2份,菟丝子3份,鹿茸片2份,旋复花2份,代赭石2份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711371634.8A CN107823625A (zh) | 2017-12-18 | 2017-12-18 | 一种治疗冠心病心肌梗死心绞痛心律失常心衰的中药散剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711371634.8A CN107823625A (zh) | 2017-12-18 | 2017-12-18 | 一种治疗冠心病心肌梗死心绞痛心律失常心衰的中药散剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107823625A true CN107823625A (zh) | 2018-03-23 |
Family
ID=61645215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711371634.8A Pending CN107823625A (zh) | 2017-12-18 | 2017-12-18 | 一种治疗冠心病心肌梗死心绞痛心律失常心衰的中药散剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107823625A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1334121A (zh) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | 一种通心络药物组合物及应用 |
CN106822852A (zh) * | 2017-04-01 | 2017-06-13 | 康明 | 治疗冠心病的药物组合物、其制备工艺及用途 |
CN107303383A (zh) * | 2016-04-21 | 2017-10-31 | 张东 | 一种对多种症状具有功效的中药组合物及其衍生物和制品 |
-
2017
- 2017-12-18 CN CN201711371634.8A patent/CN107823625A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1334121A (zh) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | 一种通心络药物组合物及应用 |
CN107303383A (zh) * | 2016-04-21 | 2017-10-31 | 张东 | 一种对多种症状具有功效的中药组合物及其衍生物和制品 |
CN106822852A (zh) * | 2017-04-01 | 2017-06-13 | 康明 | 治疗冠心病的药物组合物、其制备工艺及用途 |
Non-Patent Citations (1)
Title |
---|
曹生海等: "刘星元运用乌梅汤的经验", 《辽宁中医药大学学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101991816A (zh) | 一种治疗心脑血管疾病的中药制剂 | |
CN1895620A (zh) | 一种治疗冠心病的中药组合物 | |
CN103202879B (zh) | 一种治疗慢性心力衰竭的中药组合物及制备方法 | |
CN101711853B (zh) | 一种治疗心动过缓病症的中药组合物及其制备方法 | |
CN105030919A (zh) | 一种治疗脑出血的药物组合物 | |
CN102988696B (zh) | 一种用于治疗冠心病心绞痛的中药组合物及其用途 | |
CN102988900B (zh) | 一种治疗老年功能性便秘的中药灌肠剂 | |
CN101596302A (zh) | 一种治疗冠心病心绞痛的药物及其制备方法 | |
CN104147346A (zh) | 一种治疗冠脉弥漫性病变心绞痛的中药复方 | |
CN107823625A (zh) | 一种治疗冠心病心肌梗死心绞痛心律失常心衰的中药散剂 | |
CN102579804B (zh) | 一种治疗心绞痛的中药 | |
CN106177759A (zh) | 一种治疗冠心病心绞痛的中药复方制剂及其制备工艺 | |
CN102309561B (zh) | 一种用于预防和治疗痛风性关节炎及高尿酸血症的药物组合物 | |
CN105560835A (zh) | 一种用于治疗慢性充血性心力衰竭的药物 | |
CN107669836A (zh) | 冠心病心绞痛用中药配方及其制备方法 | |
CN104225420A (zh) | 一种治疗阴寒凝滞型冠心病的中药制剂及护理方法 | |
CN102961672A (zh) | 一种治疗心血管病兼痞满的药物及其制备方法 | |
CN105168653A (zh) | 一种用于治疗冠心病的中药组合物 | |
CN114796420A (zh) | 一种治疗非瓣膜性心房颤动的中药组合物及其中药制剂和应用 | |
CN104857459A (zh) | 一种治疗心力衰竭的中药组合物及其制备方法 | |
CN102028811B (zh) | 一种治疗消渴病的中药组合物 | |
CN104189424A (zh) | 一种治疗心力衰竭的中药组合物 | |
CN103735898A (zh) | 一种治疗心肌炎的中草药配方及制备方法 | |
CN1823890B (zh) | 治疗病毒性心肌炎的口服中药 | |
CN103169888A (zh) | 一种治疗高血压病的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190826 Address after: 130062 Taipei Street 1913, Kuancheng District, Changchun City, Jilin Province Applicant after: Shi Guijun Address before: 130000 Shuguang Road 463, Nanguan District, Changchun City, Jilin Province Applicant before: Changchun Hospital of traditional Chinese Medicine |
|
TA01 | Transfer of patent application right | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180323 |
|
WD01 | Invention patent application deemed withdrawn after publication |